Article
A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Biochemical pharmacology - 1 Dec 2011
Andrieu Thomas, Bertolini Reto, Nichols Sara E, Setoud Raschid, Frey Felix J, Baker Michael E, Frey Brigitte M
Abstract excerpt
Prostate cancer (PCa) progression is enhanced by androgen and treatment with antiandrogens represents an alternative to castration. While patients initially respond favorably to androgen ablation therapy, most experience a relapse of the disease within 1-2 years by expressing androgen receptor (AR) mutants. Such mutations, indeed, promote unfavorable agonistic behavior from classical antagonists. Here, we have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.